Market capitalization | €443.06m |
Enterprise Value | €478.09m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.13 |
P/S ratio (TTM) P/S ratio | 2.90 |
P/B ratio (TTM) P/B ratio | 2.34 |
Sales growth (TTM) Sales growth | -58.99% |
Turnover (TTM) Turnover | €152.96m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
10 Analysts have issued a Valneva forecast:
10 Analysts have issued a Valneva forecast:
Mar '24 |
+/-
%
|
||
Turnover | 153 153 |
59%
59%
|
|
Gross income | 55 55 |
31%
31%
|
|
EBITDA | - - |
-
|
EBIT (operating result) EBIT | -109 -109 |
13%
13%
|
Net profit | -24 -24 |
82%
82%
|
Figures in millions EUR.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Valneva SE is a biotech company. The firm engages in the development, production and marketing of vaccine and preventive medicine. It operates through the following segments: Commercialized Vaccines, Technologies and Services and Vaccine Candidates. The Commercialized Vaccines segment includes currently marketed vaccines of the group such as JEV and DUKORAL. The Technologies and Services segment regroups services and inventions in commercialization stage. The Vaccine Candidates segment consists of proprietary research and development programs aiming to generate new approvable products. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.
Head office | France |
CEO | Thomas Lingelbach |
Employees | 676 |
Founded | 1999 |
Website | www.valneva.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.